Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Altmann

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Ebiomedicine|March 4, 2021
Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infectionCharlotte Manisty, Thomas Alexander Treibel, Melanie Jensen, et al.
Science (New York, N.Y.)|December 2, 2021
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variantsCatherine J Reynolds, Joseph M Gibbons, Corinna Pade, et al.
Elife|December 17, 2020
Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumoniaMichaela Gregorova, Daniel Morse, Tarcisio Brignoli, et al.
Immunology|February 14, 2022
HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19Stuart Astbury, Catherine J Reynolds, David K Butler, et al.
Cell Reports. Medicine|April 27, 2022
Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infectionsAneesh Chandran, Joshua Rosenheim, Gayathri Nageswaran, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2022
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control studyJames L Alexander, Nicholas A Kennedy, Hajir Ibraheim, et al.
Iscience|June 5, 2023
Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infectionMartina Milighetti, Yanchun Peng, Cedric Tan, et al.
Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Ebiomedicine|March 4, 2021
Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infectionCharlotte Manisty, Thomas Alexander Treibel, Melanie Jensen, et al.
Science (New York, N.Y.)|December 2, 2021
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variantsCatherine J Reynolds, Joseph M Gibbons, Corinna Pade, et al.
Elife|December 17, 2020
Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumoniaMichaela Gregorova, Daniel Morse, Tarcisio Brignoli, et al.
Immunology|February 14, 2022
HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19Stuart Astbury, Catherine J Reynolds, David K Butler, et al.
Cell Reports. Medicine|April 27, 2022
Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infectionsAneesh Chandran, Joshua Rosenheim, Gayathri Nageswaran, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2022
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control studyJames L Alexander, Nicholas A Kennedy, Hajir Ibraheim, et al.
Iscience|June 5, 2023
Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infectionMartina Milighetti, Yanchun Peng, Cedric Tan, et al.
Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
Pageof 15